Efficacy of Losartan in Preventing Progression of COPD

Johns Hopkins University

Status and phase: Completed; Phase 4

Conditions: Chronic Bronchitis; Emphysema; COPD; Smoking

Treatments: Drug: Placebo; Drug: Losartan

Study type: Interventional

Funder types: Other; Industry; NIH

Identifiers

NCT00720226

1P50HL084945 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

Evidence in animals shows that losartan can prevent or reverse inflammation and lung damage due to smoking. The goal of this study is to determine whether this drug which is also used to treat hypertension can stabilize or improve lung function in people who have from chronic obstructive pulmonary disease (COPD).

Full description

Participants will be given either losartan in a dose of 50-100 mg per day for a period of one year. During that time, they will have lung function tests, breathing tests, and computed tomograms of the chest. These tests will determine whether there is inflammation in the lung and whether there is progressive involvement of the lung with COPD.

Enrollment: 106 patients

Sex: All

Ages: 40+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adults with COPD who are either active or former smokers

Exclusion criteria

• Clinical requirement or history of intolerance of angiotensin receptor blockers, serious heart, liver, kidney, neurological disease.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

106 participants in 2 patient groups, including a placebo group

Losartan

Experimental group

Description:

Losartan 100 mg daily

Treatment:

Drug: Losartan

Placebo

Placebo Comparator group

Description:

Placebo 1 pill daily

Treatment:

Drug: Placebo